Olumiant® (baricitinib – Eli Lilly and Incyte) is now approved to treat COVID-19 in hospitalized adults who require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

• In 2020, the U.S. FDA granted emergency use authorization (EAU) for Olumiant to be used alongside Veklury® (remdesivir – Gilead) to treat COVID-19 in certain patients. An EUA is still in effect for Olumiant’s use in the treatment of hospitalized pediatric patients at least two years of age who require oxygen support.
• Recommended dosing under the new FDA approval for adults is 4mg once daily for 14 days or until hospital discharge, whichever comes first.